Tufts CSDD Releases March/April 2022 Impact Report


Tufts CSDD has released the latest version of its bi-monthly Impact Report. In this March/April 2022 editionm the focus is oncost variation and mis-estimation in clinical trial budgets.

Facing limited resources and increasing operating and workforce-related costs across expanding drug development portfolios, sponsor companies are seeking ways to reign in clinical trial costs. At the same time, protocol designs continue to become more complex, resulting in higher levels of inefficiency, greater patient recruitment and retention challenges, and unplanned and unbudgeted disruptions.

Based on the results of a recent working group study, this Tufts CSDD Impact Report examines clinical trial budgets and offers insight into the factors driving commonly observed variation and cost.

The full report is available for purchase here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.